葫芦娃：获得吸入用异丙托溴铵溶液药品注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the inhalation solution of ipratropium bromide, which is indicated for the treatment of asthma and chronic obstructive pulmonary disease [1] Group 1: Product Approval - The approved specifications for the drug are 2ml: 0.25mg and 2ml: 0.5mg, which are considered equivalent to passing the consistency evaluation of generic drug quality and efficacy [1] - A total of 29 companies in China have been approved to produce this drug as of the announcement date [1] Group 2: Research and Development Investment - The company has invested a total of 5.9089 million yuan in the research and development of this product [1] Group 3: Market Uncertainty - The sales performance of the drug is subject to uncertainties influenced by policies and market factors [1]